This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

ITM 2024 SNMMI
Dinner Symposium

Get immediate access by registering today.

Register to watch full recording

Already have an account? Log in

Clinical Needs Driving Radiopharmaceutical Research and Scalable Solutions

When: Sunday, June 9th | 6:30pm - 7:30pm
Where: Toronto Convention Center | South Building, 700 Level, Room 701B

Overview

This session will examine the well-established clinical utility of beta-emitting Lu-177 therapies and the potential of alpha-emitting Ac-225 and Auger-emitting
Tb-161, ongoing research to support the development of new radiopharmaceuticals, and how a sustainable supply of isotopes is being established to address the rapidly growing demands for clinicians and researchers.

 

Attendance is free to all attendees of the SNMMI Annual Meeting.
For more information or to register to attend SNMMI click here:

SNMMI.org 

Watch the introduction below and register now to access the full program

Roger
Estafanos

Session Moderator

General Manager, ITM USA

Munir
Ghesani, MD

Expanding the use of theranostics & the clinical management of patients

Chief Medical Officer, UNITED THERANOSTICS

Danielle
Meyrick, PhD, MD

Growing Pipeline to Address Unmet Clinical Needs

Chief Medical Officer, ITM

Mark
Harfensteller, PhD

Scalable Solutions to Meet the Rapidly Growing Needs

Chief Operating Officer, ITM

Roger
Estafanos

Session Moderator

General Manager, ITM USA

Munir
Ghesani, MD

Expanding the use of theranostics & the clinical management of patients

Chief Medical Officer, UNITED THERANOSTICS

Danielle
Meyrick, PhD, MD

Growing Pipeline to Address Unmet Clinical Needs

Chief Medical Officer, ITM

Mark
Harfensteller, PhD

Scalable Solutions to Meet the Rapidly Growing Needs

Chief Operating Officer, ITM

ITM Isotope Technologies Munich SE
Lichtenbergstrasse 1
85748 Garching / Munich, Germany
Email: info(at)itm-radiopharma.com
Phone: +49 89 329 8986 6000
Fax: +49 89 329 8986 6061